<DOC>
	<DOCNO>NCT00475670</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety intravenous Herceptin without taxane first line treatment metastatic breast cancer woman relapse least 12 month minimum 10 month ( neo ) adjuvant treatment Herceptin HER2-positive early breast cancer.Patients receive either Herceptin monotherapy ( load dose 4mg/kg iv , follow weekly dos 2mg/kg iv , 8mg/kg load dose follow 3-weekly dos 6mg/kg ) Herceptin + taxane ( docetaxel 100mg/m2 iv every 3 week , paclitaxel 175mg/m2 iv every 3 week 75mg/m2 every week ) . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>least 10 month Herceptin treatment HER2positive early breast cancer ; metastatic breast cancer &gt; =12 month discontinuation Herceptin ; measurable disease . previous chemotherapy metastatic breast cancer ; brain metastasis ; invasive malignancy metastatic breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>